3rd Annual Targeted Protein Degradation Summit - Digital Event

Memo

Returning in a digital capacity, the 3rd Targeted Protein Degradation (TPD) Summit is your industry-dedicated platform that is bringing together the pioneering leaders of the biopharmaceutical industry and academia. As the most comprehensive and definitive event for the field of protein degradation, the 3rd TPD Summit is proud to showcase the very latest case studies and unique perspectives from 60+ pioneering experts who are capitalizing on this exciting therapeutic class and breaking new ground to make protein degradation the modality of choice. Via the latest data-driven case studies from industry and academic experts, successfully degrade intracellular and extracellular targets, leverage the power of the ubiquitin-proteasome system and autophagy-mediated degradation and optimize drug-like properties of next-generation protein degraders for applications in oncology and beyond. As TPD-based therapeutics continues to generate a new frontier in the field of medicine, join C-Level Executives, VPS, and Directors from leading biopharmaceutical organizations at the 3rd TPD Summit to gain a unique insight into the latest developments of the field and walk away with valuable connections and future directions to drive forward your TPD strategies. URLs:Tickets: https://go.evvnt.com/664140-2?pid=5569Brochure: https://go.evvnt.com/664140-3?pid=5569 Prices:3 Day Package: Conference and Workshop Day: USD 3348.0,2 Day Package: Conference Only: USD 2099.0,Workshop Day Only: USD 1347.0 Speakers: Jay Bradner, President, Novartis Institutes for Biomedical Research, Craig Crews, John C. Malone Professor of MCDB, Chemistry and Pharmacology, Yale University, Alessio Ciulli, Professor of Chemical and Structural Biology, University of Dundee, Matthew Disney, Professor of Chemistry and Neuroscience, Scripps Research, Daniel Nomura, Professor of Chemistry, University of California, Berkeley, Milka Kostic, Program Director of Chemical Biology, Dana-Farber Cancer Institute, Hirokazu Arimoto, Professor, Tohoku University, Dirk Trauner, Professor of Chemistry and Neuroscience, New York University, Shaomeng Wang, Warner-Lambert/ Parke-Davis Professor in Medicine; Director of Michigan Center for Therapeutic Innovation, University of Michigan, Daohong Zhou, Professor of Pharmacodynamics and Associate Director for Translation and Drug Development, University of Florida, Thomas Dick, Professor, Hackensack Meridian Health, Center for Discovery and Innovation, Courtney Aldrich, Professor, University of Minnesota, Jan Kronke, Professor, Charite Berlin, Guangrong Zheng, Associate Professor of Medicinal Chemistry, University of Florida, Jin Wang, Associate Professor, Baylor College of Medicine, Ramesh Narayanan, Associate Professor and Director of Center for Cancer Drug Discovery, University of Tennessee, Yonghao Yu, Associate Professor of Biochemistry, UT Southwestern Medical Centre, Nir London, Senior Scientist, The Weizmann Institute of Science, George Burslem, Assistant Professor, University of Pennsylvania, Amit Chouhdary, Assistant Professor, Broad Institute, Harvard Medical School and Brigham and Women's Hospital, Christina Woo, Assistant Professor, Harvard University, Jun Qi, Assistant Professor of Medicine, Dana-Farber Cancer Institute, Rebecca Beveridge, Chancellor's Fellow and UKRI Future Leaders Fellow, University of Strathclyde, Ashley Modell, Postdoctoral Associate, Broad Institute, Harvard Medical School and Brigham and Women's Hospital, Sachini Siriwardena, Postdoctoral Associate, Broad Institute, Harvard Medical School and Brigham and Women's Hospital, Yu Shen, Director of Cancer Biology, AbbVie, Ray Deshaies, Senior Vice President of Global Research Amgen, Ian Churcher, Chief Scientific Officer, Amphista Therapeutics, John Houston, President and Chief Executive Officer, Arvinas, Scott Edmondson, Director and Head of Boston Oncology Chemistry, AstraZeneca, Philipp Cromm, Discovery Chemist, Bayer, James Tonra, Chief Scientific Officer, BeyondSpring Pharmaceuticals, Frank Mercurio, Chief Scientific Officer, BioTheryx, Stewart Fisher, Chief Scientific Officer, C4 Therapeutics, Michael Plewe, Vice President of Medicinal Chemistry, Cullgen, Bomie Han, Research Advisor, Eli Lilly, Greg Verdine, Chairman, President and Chief Executive Officer, Fog Pharma, James Winkler, Head of Degrader Technology, Frontier Medicines, Ingrid Wertz, Principal Scientist and Project Team Lead, Genentech, Markus Queisser, Scientific Leader, GlaxoSmithKline, Stephanos Ioannidis, Vice President and Head of Chemistry, H3 Biomedicine, Taavi Neklesa, Vice President of Biology, Halda Therapeutics, Jennifer Venable, Senior Scientific Director, Janssen Pharmaceuticals, Nello Mainolfi, Founder, President and Chief Executive Officer, Kymera Therapeutics, Haojing Rong, Vice President of Pre-Clinical Development, Kymera Therapeutics, Richard Glynne, Chief Scientific Officer, Lycia Therapeutics, Amine Sadok, Director of Biology, Monte Rosa Therapeutics, Arthur Sands, Chief Executive Officer, Nurix Therapeutics, Gwenn Hansen, Senior Vice President of Research, Nurix Therapeutics, Daniel Joo, Vice President of Biology, Oerth Bio, James Schiemer, Senior Scientist, Pfizer, Benedict Cross, Chief Technology Officer, PhoreMost, Kandaswamy Vijayan, Chief Executive Officer, Plexium, Suresh Kumar, Senior Director of Research and Development, Progenra, Kevin Foley, Chief Scientific Officer, Ranok Therapeutics, Matthias Wittwer, DMPK/PD Project Leader, Roche, Laura Itzhaki, Professor and Chief Scientific Officer, University of Cambridge and PolyProx Therapeutics, Danette Daniels, Group Leader of Research and Development, Promega, David Fry, Distinguished Research Leader, NJ Biopharmaceuticals, Agustina Rodriguez- Granillo Principal Scientist II Schrodinger, Michael Drummond, Scientific Applications Manager, Chemical Computing Group, Karteek Kadimisetty, Assistant Director of Research and Development, LifeSensors Date and Time: On Tuesday October 13, 2020 at 8:00 am (ends Thursday October 15, 2020 at 5:30 pm)